The U.S. Food and Drug Administration on Friday declined to approve Alkermes Plc's opioid-based depression treatment, citing the need for additional data to prove the effectiveness of the drug.
from Reuters: Health News https://reut.rs/2Bhi3eG
via IFTTT
from Reuters: Health News https://reut.rs/2Bhi3eG
via IFTTT
إرسال تعليق